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SUMMARY 
Mycobacterial infection-related morbidity and mortality in patients following 
cardiopulmonary bypass surgery is high and there is a growing need for a consensus-based 
expert opinion to provide international guidance for diagnosing, preventing, and treating in 
these patients. In this document the International Society for Cardiovascular Infectious 
Diseases (ISCVID) covers aspects of prevention (field of hospital epidemiology), clinical 
management (infectious disease specialists, cardiac surgeons, ophthalmologists, others), 
laboratory diagnostics (microbiologists, molecular diagnostics), device management 
(perfusionists, cardiac surgeons), and public health aspects.  
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1. Background 
Mycobacterium chimaera is an environmental, slowly growing non-tuberculous 
mycobacterium (NTM) [1] and, until recently, would have been identified by most clinical 
microbiology laboratories as M. intracellulare or M. avium complex (MAC). Prior to this 
current global outbreak, M. chimaera was recognized as a cause of respiratory and 
disseminated infections among immunocompromised patients [2]. Since 2013, a global 
outbreak of disseminated M. chimaera has been ongoing among patients who underwent 
open-chest surgery with cardiopulmonary bypass (CPB) [3–25] with all cases linked to 
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contamination of a specific brand (Stockert 3T; LivaNova, London, UK) of heater–cooler 
device (HCD) used in CPB [4,26–28]. CPB temporarily replaces cardiopulmonary function 
during surgery with maintenance of blood flow and oxygenation – thus the common term of 
‘heart–lung machine’ for the CPB pump. HCDs circulate water through heat exchangers and 
warm or cool blood passing through the CPB and cardioplegia solution circuits. 
Extracorporeal circulation provides a bloodless field for surgery and maintains vital organ 
perfusion. 
M. chimaera has caused disseminated infections following a variety of open-chest 
surgeries with CPB, including placement of prosthetic heart valves, prosthetic aortic grafts, 
and mechanical circulatory support devices [3,7], with a proclivity for ocular involvement 
[5,15] and granulomatous inflammation in multiple organs in some cases that prompted an 
initial misdiagnosis of sarcoidosis [3,14,15,29]. Infections following on-pump coronary artery 
bypass graft (CABG) have also been rarely reported [9,30]. Because there are no international 
clinical practice guidelines that provide recommendations in the diagnosis, management, and 
prevention of disseminated M. chimaera infections that occur following CPB a multinational 
collaboration was convened for the development of guidelines that are outlined in this 
document.  
2. Scope and aims 
In 2017, the International Society for Cardiovascular Infectious Diseases (ISCVID) 
recognized the importance of disseminated mycobacterial infections in patients following 
open-chest surgery with CPB and the growing need for international guidance on diagnosis, 
management and prevention of these infections. Accordingly, the primary aims of this 
document were: (i) to provide an update on M. chimaera epidemiology and risk factors, (ii) to 
develop guidelines for diagnosis and management in individual patients, and (iii) to outline 
infection prevention and control recommendations. This clinical practice guideline was 
developed by expert consensus after review of available literature. An evidence-based scoring 
system that was used in the European Society of Cardiology guidelines on infective 
endocarditis was included in the novel recommendations designated herein (Table Ia,b) [31]. 
3. Guidelines assembly and conflicts of interest 
During the bi-annual ISCVID meeting in Dublin in 2017, an expert consensus group, 
including infectious diseases specialists, hospital epidemiologists, cardiologists, pathologists, 
radiologists, and cardiac surgeons, formed a task force to develop recommendations on 
diagnosis, treatment, and prevention of cardiovascular infections due to M. chimaera. 
Members of this expert group were selected by the ISCVID council to represent a variety of 
professionals involved in the medical care of patients with cardiovascular infectious diseases. 
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Moreover, global representatives participated in development of these recommendations. The 
participants included those with expertise in infection prevention and control, clinical patient 
management (infectious diseases specialists, cardiac surgeons, ophthalmologists, 
anaesthesiologists), mycobacteriology laboratory diagnostics (microbiologists with 
experience in mycobacteriology and molecular diagnostics), device management 
(perfusionists, infection control specialists), and public health. Participants declared whether 
they had conflicts of interest which would require disclosure of financial or other interests that 
could constitute actual, potential, or apparent conflicts. The expert group completed a 
literature review of studies published since 2013, when the first two cases were published [3]. 
Medline was searched through the PubMed.gov database using the terms Mycobacterium 
chimaera or M. chimaera with the MeSH terms ‘treatment’, ‘cardiac’, ‘HCD’, ‘infection 
control’ as well as specific antimicrobials and classes of antimicrobials. Only English 
language articles were included because the panel members could not reliably review non-
English language studies. 
4. Epidemiology and risk factors  
4.1. Epidemiology and risk factors for HCD-associated M. chimaera infection 
The absolute risk of acquiring M. chimaera infection is much lower than the risk of 
other types of infection that complicate open-chest surgeries with CPB including deep sternal 
surgical site infections (SSIs), hospital-acquired pneumonias or urinary tract infections, and 
vascular access device infections [8,14]. The estimated risk for M. chimaera infection in 
patients undergoing open-chest surgery necessitating CPB in Switzerland was 11 cases per 
14,045 patients with valve procedures, resulting in 0.78 cases per 1000 procedures (95% 
confidence interval (CI): 0.41–1.45) [32]. In the UK, 16 cases in 112,644 patients with open-
chest procedures were initially identified, resulting in 0.14 cases per 1000 procedures (95% 
CI: 0.08–0.23) [8]. In the USA, numerous hospital-specific prevalence rates range from 1 per 
1000 to 1 per 10,000 [26]. Given the long incubation periods and observed change in risk, 
these estimates are not directly comparable as they are dependent on the years of surgery 
included and time-point at which the risk estimates were calculated [8]. 
Reported risk factors for M. chimaera infection pertain to the operative procedure 
(aortic surgery with highest risk) [9], length of exposure to a running HCD [14], specific 
HCD brand [28], year of manufacture of HCD [33], the applied HCD disinfection measures 
[34], the distance and positioning of HCD in the operating room (OR) [4,33], and the OR 
ventilation system [35]. Generation of aerosols from contaminated water systems of 
operational HCDs may have reached the surgical site through airflow generated by its cooling 
fans [8]. To date, all clinical cases related to open-chest surgery with CPB have been 
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associated with the use of Stockert 3T-HCDs (subsequently denoted ‘3T-HCD’) [26–
28,30,36,37], which have a market share of about 70%. M. chimaera has been cultured in 
hospital tap water [38] and from water of most types of HCD, and extracorporeal membrane 
oxygenation (ECMOs) water tanks on the market [39,40]. However, available air sample 
culture results from HCDs other than 3T have been reported to be negative [28,37]. 
According to a recent study, air flow direction, location of cooling ventilators, continuous 
cooling of the water tank at 4°C, and an electronic reminder of disinfection cycle are four 
relevant differences between the 3T-HCD and Maquet HCU30 and HCU40, which are HCD 
models, that may contribute to differential infection risk [6]. No published data exist on the 
respective safety aspects of several other HCD brands and models. Changes in recommended 
disinfection procedures by LivaNova in September 2014 were not successful in eliminating 
the risk of M. chimaera contamination [41]. Therefore, LivaNova implemented a device 
modification with installation of an internal sealing and vacuum system on existing 3T-HCD 
devices in 2017 [42]. Safety data collected following this modification, however, have not 
been published. 
HCDs may be positioned adjacent to the CBP pump, and the exhaust airflow from the 
HCD may be directed towards the operating field, thus contributing to the risk of M. chimaera 
infection. An OR assessment of 3T-HCD exhaust demonstrated a higher concentration of 
cumulative particles measured behind the 3T-HCD (near the exhaust fan) than at the surgical 
field over a 180 min run-time [43]. Using smoke testing, laminar flow ventilation was 
insufficient to prevent aerosols containing M. chimaera generated by the 3T-HCD and 
circulated by the HCD exhaust fan from dispersing towards the surgical field [35,44].  
Interestingly, only one suspected pulmonary M. chimaera infection has been reported 
among exposed OR personnel [45]. Although factors responsible for this observation have not 
been defined, hypotheses include: (i) M. chimaera pulmonary disease will only affect those 
with pre-existing pulmonary diseases (e.g. bronchiectasis) or with increased susceptibility to 
mycobacterial disease; (ii) concentration of M. chimaera in the air of the OR may not be high 
enough to cause pulmonary infection, especially in persons without risk factors for 
developing disease; and (iii) surgical mask use in the OR may provide protection. 
Identification of other potential respiratory pathogens, including Legionella species, in HCD 
water circuits has previously been recognized as a potential threat to patients and theatre staff 
[8]. 
4.2. Population at risk 
Based on the evidence to date, the population at risk of disseminated M. chimaera 
infection includes all patients undergoing open-chest surgery with a 3T-HCD running during 
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surgery, with the implantation of prostheses (e.g. prosthetic valves, vascular grafts, ventricular 
assist devices) increasing the risk. 3T-HCDs have also been associated with NTM infections 
other than M. chimaera [46]. Patients who underwent a cardiac procedure with ‘standby’ CPB 
and therefore a running ‘standby’ 3T-HCD have an unquantified risk. In contrast to 
pulmonary NTM disease, where NTM-containing aerosols lead to pulmonary infection in 
patients with significant underlying structural lung disease (especially in those with 
underlying bronchiectasis) or who are immunocompromised [47], the transmission route of 
HCD-related M. chimaera infection is non-inhalational and infection can occur in patients 
without previously known immune deficiency. The likely route of transmission for these non-
pulmonary M. chimaera infections is direct contamination of the open-chest cavity with M. 
chimaera-containing aerosols during cardiac surgery. Although the majority of infections 
have followed open-chest cardiac surgery, infections have also been reported among patients 
following minimally invasive cardiac surgery [21]. The hypothesized route of exposure 
among the latter is contamination of surgical equipment or grafts in the OR by 3T-HCD-
generated bio-aerosols prior to use or implantation during surgery. These infections may 
involve the heart, due to valve/graft replacements, and may widely disseminate to involve a 
panoply of body-sites including kidney, liver, bone marrow, bone, vertebra, skin, brain, and 
choroid. Cardiac conditions at risk of M. chimaera infections are listed in Table II.  
5. Multidisciplinary hospital patient management 
Recommendation 
• Management of M. chimaera-infected patients by an ‘Endocarditis Team’ is 
recommended (Class I, Level C). 
The Task Force strongly supports management of M. chimaera-infected patients by a 
multidisciplinary ‘Endocarditis Team’ [31]. Typically, initial M. chimaera infection 
symptoms are non-specific and often depend on the first body-site or organ involved, the 
surgical procedure performed, the underlying cardiac disease, and the baseline immunological 
status of the patient. Hence, the patient may present initially to a variety of medical 
specialties. Once infection is diagnosed, expertise from various medical specialties is needed 
including infectious diseases physicians, infection prevention and control practitioners, 
microbiologists, cardiologists, cardiac surgeons, ophthalmologists, internal medicine 
specialists, pharmacists, as well as other specialties. Consultation with cardiac imaging 
specialists is recommended, as echocardiography and nuclear imaging with positron emission 
tomography/computed tomography are often critical in the diagnosis of infection, determining 
the extent of dissemination, and follow-up after treatment. Due to the complexity of antibiotic 
therapy, potential adverse drug effects and drug–drug interactions, antimycobacterial 
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treatment should be guided by an infectious disease physician in close collaboration with a 
laboratory microbiologist with expertise in mycobacteriology as well as a clinical pharmacist. 
Despite the high perioperative risk with resection/excisional surgery, the outcome of patients 
with disseminated implant-associated infections may be improved when infected prosthetic 
material is removed [7,9]. Serial discussions with the surgical team and the anaesthesiologist 
are warranted to determine optimal timing of surgery once a surgical indication is recognized.  
6. Diagnosis of M. chimaera infection 
6.1. Clinical features 
The diagnosis of cardiac M. chimaera infection can be difficult as initial symptoms 
may be non-specific, subtle, and appear months to years after surgery [7,8,14,15]. 
Extrathoracic symptoms may precede cardiac or vascular manifestations [7,10,48] and signs 
of cardiac infection may be absent and detected only at surgery or post-mortem examination 
[3,10,49]. Symptom development occurs, on average, 15–17 months post surgery, but the 
incubation period can range from six weeks to more than five years [9,12,50]. Due, in part, to 
the long incubation period, clinician suspicion of disseminated M. chimaera infection is often 
low at initial presentation [13]. Non-specific and indolent symptoms often prompt alternative 
diagnoses [7,14,15]. It is not unusual for affected patients to consult with a variety of 
specialists before a correct diagnosis is made. Common reported symptoms are prolonged 
fever, weight loss, generalized malaise and night sweats, with the addition of failure-to-thrive 
in infants [13]. The physical examination is frequently normal, but in some patients (new 
onset) heart murmur, signs of embolic complications or hepatosplenomegaly, local signs of 
sternal SSI, or chorioretinitis are noted. 
Cardiovascular diagnoses include prosthetic valve endocarditis [7–10,13,20,21,30], 
aortic graft infections [7,9,13,15,49], myocarditis [3], infected pseudoaneurysms [22], and 
cardiovascular implantable electronic device infections [12] or mechanical circulatory support 
device infections [19]. Infections following on-pump CABG procedures [30] and infections 
after minimally invasive mitral valve procedures have been rarely reported [21]. Patients with 
cardiovascular infection due to M. chimaera may present with chest pain or signs of sternal 
SSIs [8,13,14] or mediastinitis [8,16]. Disseminated (extrathoracic) manifestations with 
bacteraemia may involve a variety of organs, including the lung, spleen, bone marrow, 
kidney, liver, brain, skin, and bone [3,7,8,10,13–15,20,21,49]. Disseminated M. chimaera 
infections also have a proclivity for ocular [5,15] and central nervous system [7] involvement. 
Atypical presentations are common [12–14,22,30] and a high index of suspicion is needed to 
avoid delays in diagnosis. In some cases, a diagnosis of presumptive sarcoidosis has been 
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made [3,7,13,48] based on granulomatous tissue formation leading to inappropriate 
immunosuppressive treatment.  
Many patients present with evidence of disseminated disease that may include hepatic 
involvement (elevated transaminases and/or alkaline phosphatase) [18], nephritis (impaired 
renal function), pneumonitis (impaired diffusion capacity on whole body plethysmography) 
[3], bone marrow involvement with cytopenia (anaemia, leucocytopenia, and/or 
thrombocytopenia [7,15]) or haemophagocytic syndrome [12], spine involvement with 
spondylitis and spondylodiscitis [30], arthritis [7], or splenomegaly. A consistent 
histopathologic finding upon biopsy of involved body sites is the presence of non-caseating 
granulomas, often with negative acid-fast bacilli (AFB) smears. Some patients also develop 
neurological complications with vasculitis of the brain, encephalitis or chorioretinitis 
[7,15,51]. 
6.1.1. Chorioretinitis 
Chorioretinal lesions may be present in patients presenting with disseminated M. 
chimaera infection [5,15,52]. The patients present with bilateral white-yellowish chorioretinal 
lesions varying from a few lesions to widespread miliary disease, and a subset of patients 
have had additional signs of mild anterior uveitis, intermediate uveitis or optic disc swelling 
[5,52]. Depending on the location of the lesions and the presence of complications such as 
choroidal neovascularization, these patients might not report visual complaints. 
Choroidal manifestations in patients with disseminated M. chimaera infection are an 
important clue to this disease. A classification of choroidal lesions based on multi-modal 
imaging is detailed in Table III, and a recommendation for screening and follow-up 
ophthalmological examinations in patients with suspected or confirmed M. chimaera infection 
is included in Table IV.  
6.1.2. Immune reconstitution inflammatory response syndrome 
An immune reconstitution inflammatory syndrome (IRIS) can complicate tuberculosis 
treatment with a variety of clinical tuberculosis manifestations, with human 
immunodeficiency virus (HIV) infection being an important risk factor [53]. Nontuberculous 
mycobacteria usually cause IRIS only in HIV-infected patients [54]. In case of disseminated 
M. chimaera infection, several manifestations occurring after initiation of treatment have 
represented an IRIS including fever, abscess formations in various body sites (lymph nodes, 
ovary, spleen, prostate and bone), pancytopenia or chorioretinitis [48]. Patients have typically 
been treated with corticosteroids (1 mg/kg per body weight) as an adjunct to 
antimycobacterial therapy. Currently, the long-term outcome and the spectrum of disease of 
potential M. chimaera-related IRIS are yet to be fully defined.  
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6.2. Imaging techniques 
Recommendations 
• Transoesophageal echocardiogram for detection of cardiac vegetations, aortic root 
collections, and evaluation of valvular function is recommended (Class I, Level C). 
• 
18F-Fluorodeoxy-glucose positron emission tomography (PET)/computed tomography 
(CT) imaging in case of suspected aortic graft infection or fever of unknown origin 
(FUO) should be considered (Class IIa, Level C). 
In cases of suspected M. chimaera infection, echocardiography is central in the 
diagnosis, surgical assessment and postoperative follow-up [7]. Vegetations, aortic root 
abscess, valve dysfunction including regurgitation and paravalvular or periprosthetic 
complications can be identified. Transthoracic echocardiography (TTE) should be performed 
as part of an initial assessment. However, as most cases have been associated with the 
presence of prosthetic material, additional transesophageal echocardiography (TOE) is 
recommended, because of the increased sensitivity of TOE as compared to that of TTE. If 
extrathoracic infections precede cardiac manifestations, initial echocardiography may be 
normal [10,15,20,21]. Therefore, repeat TOEs may be needed, especially among patients who 
do not respond well to antimicrobial treatment. For patients with prosthetic valve endocarditis 
and aortic graft infections, other imaging techniques such as PET with CT or cardiac contrast-
enhanced CT are recommended [15,55,56]. PET/CT, for example, can detect cardiovascular 
involvement and extracardiac complications when TOE is negative [15,21,56–60], and 
PET/CT is helpful in treatment monitoring [61]. 
6.3. Microbiological diagnosis 
6.3.1. Laboratory culture methods  
Mycobacteria only grow in and on specific media; thus, a high index of suspicion on 
the side of the clinician is important and correct culture materials (e.g. heparin or sodium 
citrate blood send for mycobacterial cultures) need to be used. A positive AFB culture for 
mycobacteria from a specimen taken from a sterile extrapulmonary site (blood, purulent 
material, bone marrow, tissue, or implanted prosthetic material) should be considered a 
suspect case. If there is no mycobacterial growth after eight weeks of incubation, the culture 
is considered negative. Following growth, species identification and antimicrobial 
susceptibility testing (AST) are necessary to inform treatment. Laboratory culture methods are 
listed in Table V. For all purulent materials and tissue samples, a combination of solid media 
(Middlebrook 7H10 or 7H11 or Lowenstein–Jensen) and mycobacterial growth indicator 
tubes (MGIT; BD, Franklin Lakes, NJ, USA) or other liquid systems such as VersaTrek 
(Thermo Fisher, Cleveland, OH, USA) should be used to maximize sensitivity [62]. 
9 
 
According to a recent case series of 30 patients with M. chimaera in the UK, the overall 
diagnostic sensitivity of one single mycobacterial blood culture is estimated to be 68% with 
multiple blood or urine cultures increasing the diagnostic yield [9]. An even higher index of 
suspicion is needed to repeat blood cultures specifically for mycobacteria when initial cultures 
have not produced growth or if a bacterial PVE is already diagnosed [63]. 
HCD water samples, if performed, should be cultured as recommended by the ECDC 
[64]. However, the majority of isolates from HCDs contained mixed populations of two or 
more strains which led to potential mismatches between environmental and patient cultures in 
one survey [28].  
6.3.2. Molecular diagnosis  
Most laboratory methods identify an M. chimaera isolate as a member of the M. avium 
complex (MAC) and not all laboratories are able to differentiate M. chimaera and M. 
intracellulare. The complete 16S rDNA gene sequences of MAC species differ by only six to 
10 base pairs, and only one base pair discriminates M. chimaera and M. intracellulare [1]. 
Therefore, sequencing of the 16S–23S internal transcribed spacer region (ITS) has been 
suggested, albeit rarely available in clinical laboratories [65]. Recent experiences show that 
sequencing of the first 500 bp of the 16S rRNA gene (rrs) is sufficient to discriminate M. 
chimaera and M. intracellulare (included in MicroSeq; Applied Biosystems, Thermo Fisher, 
Foster City, CA, USA). 
Another method is hsp65 sequencing [1]. Researchers have developed a novel reverse 
hybridization of PCR product-based assay (GenoType NTM-DR ver. 1.0; Hain Lifescience, 
Nehren, Germany) with 100% specificity for identifying M. chimaera in 173 isolates [66,67]. 
Because the differentiation of MAC species is challenging and expensive in a diagnostic 
setting, Bruker has recently developed an improved algorithm to differentiate pathogenic 
species based on differential spectral peak signatures, by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry on a commercially available platform. 
The results are promising with identification of 100% of the M. intracellulare and 82% of the 
M. chimaera isolates [68].  
A TaqMan quantitative polymerase chain reaction (qPCR) assay has been developed 
to facilitate a rapid diagnosis of M. chimaera infection [69]. With this method, M. chimaera 
could be detected ex vivo at low concentrations (with a limit of 100 cfu/mL in whole blood) in 
human blood samples [69]. Of note, blood anticoagulated with sodium citrate or EDTA and 
not heparin should be used for PCR testing. 
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6.3.3. Whole genome sequencing  
For genotyping, whole genome sequencing of clinical and HCD isolates should be the 
preferred method to confirm relatedness to the HCD outbreak strain [8,26–28,37,70]. 
Phylogenetic signature single nucleotide polymorphisms (SNPs) can also be used to identify 
certain groups/clades of M. chimaera, including the outbreak clade [28]. Karius (Redwood 
City, CA, USA) developed a next-generation sequencing test specifically to detect M. 
chimaera in plasma samples [71,72].  
Remarkably, whole genome sequencing results have supported a common source of 
the current global M. chimaera outbreak. Most studies revealed that the majority of patient 
isolates, HCD water and air isolates from multiple countries were very closely related with 
differences of single nucleotide polymorphisms of fewer than 10 variants [8,26–28,37,70]. 
One large European sequencing study [28] included 250 isolates of M. chimaera and all but 
one isolate from a patient with prior open-heart surgeries clustered in the outbreak group 1.1 
(median of only four SNP differences among them). This group also included HCD water and 
air isolates and one isolate from the LivaNova factory and a Maquet ECMO device. However, 
there were several HCD isolates not clustering in group 1.1. Additionally, two studies 
revealed that M. chimaera could be detected in factory-new assembled HCDs and from the 
pump assembly area [28,30] implicating contamination with M. chimaera at the LivaNova 
factory as the most likely source of the worldwide outbreak. Most researchers are concerned 
that all HCD made by this manufacturer over the past decade may have been contaminated 
with the M. chimaera outbreak strain [37].  
6.3.4. Microbiological diagnostic algorithm for suspected M. chimaera infection 
Recommendations 
• Among patients with prosthetic valves/rings, aortic grafts and mechanical circulatory 
devices, conventional blood cultures off antibiotics are recommended for any 
undefined febrile illness for which antimicrobials are being considered (Class I, Level 
C). 
• If the above are negative and cardiovascular infection is still in the differential based 
on when the patient was exposed to 3T-HCD, multiple mycobacterial (heparin or 
sodium citrate) blood cultures are recommended (Class I, Level C). Consider also 
specific mycobacterium genus-specific PCR from whole blood (Class IIa, Level C). 
• AFB stain and culture of cardiac or other affected tissue (sputum, urine, kidney, liver, 
skin) are recommended (Class I, Level C). Consider also species-specific PCR or 
mycobacterium genus-specific PCR followed by next-generation sequencing from 
plasma (Class IIa, Level C). 
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• If cytopenias are present, bone marrow biopsy should be considered for histology, 
staining and mycobacterial culture (Class IIa, Level C). 
• In case of FUO, if initial mycobacterial blood cultures are unrevealing, repeat 
mycobacterial blood cultures and mycobacterium genus-specific PCR from whole 
blood or NGS from plasma should be considered (Class IIa, Level C). 
Early detection of cardiovascular infection (regardless of pathogen) is important. In 
most instances the pathogen will not be M. chimaera. Therefore, blood cultures off antibiotics 
are important, and physicians need to routinely encourage all patients with cardiac valves, 
repairs, or history of infective endocarditis to request blood cultures before being placed on 
empiric antimicrobials for a febrile illness [73].  
The crucial point in patients with suspected M. chimaera infection is a prior history of 
surgery requiring CPB (exposure criterion). When conventional blood cultures are negative 
and infective endocarditis or aortic graft infection is suspected, serological testing as 
suggested for culture-negative endocarditis should be done [31]. Bacterial blood cultures (i.e. 
non-mycobacterial) should be incubated for at least seven to 10 days, whereas mycobacterial 
blood cultures should be incubated for at least 56 days. In cases involving redo cardiac 
surgery, tissue cultures (for both bacteria as well as mycobacteria), broad-range and 
mycobacterium genus-specific PCR (covering NTM) as well as histopathology should be 
performed. A laboratory diagnostic algorithm in case of suspected M. chimaera infection is 
provided in Figure 1.  
6.4. Histopathological diagnosis of M. chimaera infection 
Recommendations 
• Resected cardiac valve or other infected tissue and embolic fragments should be 
examined for possible mycobacterial infection (Class I, Level C). 
• Mycobacterium genus-specific PCR should be considered if histopathology shows 
non-caseating granulomas and foamy swollen macrophages with/without acid-fast 
bacilli (Class IIa, Level C). 
The histopathological standard to confirm a diagnosis of infective endocarditis in 
patients undergoing surgery for proven or suspected endocarditis is the presence of 
inflammation, neovascularization, and organisms. AFB stains from unfixed valve tissue 
should be done in all cases if a pathogen is not identified by conventional bacteriological 
methods. The detection of non-caseating granulomas and foamy swollen macrophages 
with/without AFB is consistent with NTM infection, including those by M. chimaera in the 
appropriate clinical setting [3,5,7]. Granulomatous lesions have also been described in the 
liver, kidney, lung, choroid, bone, myocardium, bone marrow, skin, and muscles among 
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patients with disseminated M. chimaera infection [3,7,18]. Resected cardiac valve or other 
infected tissue and embolic fragments should be examined for suspected mycobacterial 
infection. Additionally, the tissue sample should be sent to a microbiology laboratory for 
identification of micro-organisms and performance of mycobacterium genus-specific PCR 
[74]. Because the sensitivity of PCRs performed on paraffin-embedded specimens is 
generally lower as compared to that of natural specimens [3,75], a short-amplicon PCR 
targeting the mycobacterial hsp65 gene may be considered [76].  
6.5. Diagnostic criteria 
Diagnostic criteria for M. chimaera infection are presented in Table V. The long 
latency and the protean clinical presentation complicate securing an early diagnosis. Thus, the 
criteria used in the 2015 European Society of Cardiology guidelines for the diagnosis of IE 
are not applicable in these patients[31]. Moreover, sporadic cases with bacteraemia and 
disseminated infections without obvious signs of valve involvement have occurred [3,49].  
7. Antimicrobial therapy 
7.1. Antimicrobial therapy 
Recommendations 
• Use of combination therapy with azithromycin (or clarithromycin) with ethambutol, 
and a rifamycin (Class I, Level C), whereby the macrolide is the cornerstone of 
therapy, thus should not be given as a monotherapy at any time (Class III, Level C). 
• Amikacin is recommended and continued for as long as tolerated via peripherally 
inserted central catheter as outpatient parenteral antibiotic therapy (Class IIa, Level 
C).  
Table VI lists regimens for M. chimaera treatment. Currently, we are unable to 
provide a definitive recommendation regarding the duration of treatment. However, some 
investigators have followed with monthly mycobacterial blood cultures and treatment for a 
minimum of 12 months after conversion of blood cultures or redo surgery. For patients who 
are not candidates for additional cardiovascular surgery, long-term suppressive antibiotic 
therapy such as used in disseminated MAC infection might be considered. 
Combination therapy consisting of azithromycin (or clarithromycin) with ethambutol, 
and a rifamycin, is recommended for treatment of disseminated MAC infections among 
people living with HIV infection [47]. A macrolide is considered the cornerstone of therapy 
for MAC infections [47], whereas the combination with a rifamycin is to prevent macrolide 
resistance selection. Drug–drug interaction due to azithromycin and rifamycin is less [77] and 
the azithromycin tolerability is in general better than for clarithromycin, thus azithromycin is 
preferred over clarithromycin. We strongly discourage one- or two-drug therapy (especially 
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macrolide monotherapy) due to subsequent rapid development of macrolide resistance due to 
a 23S rRNA gene mutation [47,78,79] and of amikacin resistance due to a 16S rRNA gene 
mutation [79]. This resistance has been observed in disseminated disease due to HIV and in 
pulmonary disease treated with these agents.  
During the initial (and perioperative) phase, intravenous amikacin is recommended for 
six to 12 weeks to increase the speed of sterilization of blood cultures and valves/abscesses, 
and subsequently amikacin treatment should be continued as long as tolerated. Due to the 
severity of M. chimaera infection, many clinicians added a fifth antimicrobial agent to the 
regimen, such as clofazimine, which in vitro has shown synergistic effects with amikacin 
[80]. Moxifloxacin [81] or linezolid are alternatives; however, since the modal MICs of 
moxifloxacin and linezolid are high this is of questionable benefit [82]. There are limited in-
vitro data regarding antibacterial activity of bedaquiline against MAC [62,83–85], although 
off-label use for M. chimaera treatment has been reported in several countries. 
7.2. Adverse drug reactions of antimicrobial agents and therapeutic drug monitoring 
Recommendations 
• Monitoring of vestibular function and audiograms is recommended (monthly in 
patients receiving amikacin; every second month in patients receiving macrolides) 
(Class I, Level C). 
• Periodic ophthalmologic examinations with visual acuity, red–green colour 
discrimination, confrontation visual field testing, and dilated fundus examination is 
recommended in patients receiving ethambutol, linezolid, and/or rifabutin (Class I, 
Level C). 
• Monthly electrocardiograms are recommended in patients receiving macrolides, 
quinolones, clofazimine, linezolid, and bedaquiline (Class I, Level C). 
• Weekly therapeutic drug monitoring (TDM) is recommended in patients receiving 
amikacin. In patients with renal insufficiency receiving ethambutol, TDM is 
recommended at baseline and until steady state of therapeutic levels (Class I, Level 
C). 
• Monitoring of macrolide blood levels may be considered especially when rifampin is 
combined with clarithromycin (Class IIb, Level C).  
Many patients with disseminated M. chimaera infection experience adverse drug 
reactions [7] due to innate toxicity. Antimycobacterial antibiotics with M. chimaera activity 
and their more common adverse drug reactions are listed in Table VII. Auditory and 
vestibular function may be impaired by amikacin, clarithromycin, and azithromycin, and 
vestibular function screening and audiograms should be monitored. In addition, renal function 
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should be monitored at least once weekly in patients who receive amikacin. Due to increased 
ocular toxicity of ethambutol, rifabutin, and linezolid [86], baseline and then periodic 
ophthalmologic examinations with visual acuity (ethambutol/rifabutin), red–green colour 
discrimination (ethambutol), and dilated fundus examination are recommended. This is 
needed if they have infection-related and/or IRIS-related ocular involvement [52]. Due to the 
risk of QTc-interval prolongation (associated with 
macrolide/rifabutin/bedaquiline/moxifloxacin and linezolid treatment) monthly 
electrocardiograms are recommended.  
Therapeutic drug monitoring (TDM) is always recommended in patients receiving 
amikacin treatment, and more closely in patients with impaired renal function. Clarithromycin 
enhances rifabutin toxicity (especially uveitis), whereas rifampicin lowers clarithromycin 
serum drug levels [77,87]. However, this has not been shown to impact clinical outcome. 
Since low macrolide drug concentrations due to drug–drug interactions have been described 
[88], monitoring for azithromycin or clarithromycin blood levels should be considered among 
all patients with M. chimaera infection [89].  
7.3. Susceptibility to antimicrobial agents 
Recommendations 
• Antimicrobial susceptibility testing of M. chimaera isolates should be performed by 
experienced reference laboratories (Class I, Level C). 
• M. chimaera isolates should be saved for future testing if no baseline AST has been 
performed (Class I, Level C). 
• Clarithromycin and amikacin MIC testing is recommended (Class I, Level C). 
Criteria for AST of NTM were established by the Clinical and Laboratory Standards 
Institute (CLSI) in November 2018. Breakpoints for antimicrobials used in the treatment of 
NTM infections were re-defined in the M24Ed3 and M62Ed1 CLSI documents, respectively 
[90,91]. To ensure optimal results, AST of M. chimaera isolates should be performed by 
experienced reference laboratories [92]. Baseline macrolide AST should be performed for 
clarithromycin, as the solubility at high concentrations is increased as compared to that of 
azithromycin [79,93,94]. Furthermore AST is recommended for (i) blood culture isolates 
from patients receiving macrolides, (ii) clinically significant isolates of patients who received 
macrolide treatment, and (iii) isolates recovered from patients with relapsing infection 
following completion of a macrolide-containing regimen. As in other clinically relevant NTM 
infections, M. chimaera isolates should be saved for future testing if no baseline AST has 
been performed [79,93,94].  
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The minimum inhibitory concentration (MIC) of antimicrobials to which an 
organism’s growth is inhibited (in µg/mL, indexed to base 1) should be determined in slowly 
growing mycobacteria by broth microdilution in Mueller–Hinton broth [93,94]. All baseline 
M. chimaera clinical isolates regardless of source have very similar MICs to any drug. It 
remains unclear if the fact that post-CPB surgery infections have a common source of 
infection contributes to the particular AST pattern. Wild-type M. chimaera strains are 
susceptible to macrolides [7,15,95] and, to date, no isolate with clarithromycin resistance has 
been recovered [7,15,82]. One patient who received prolonged macrolide treatment and 
suffered infection relapse had an isolate that demonstrated intermediate resistance to 
clarithromycin (MIC of >16 to >32 µg/mL depending on pH) [52].  
Routine susceptibility testing of antimycobacterial agents other than clarithromycin is 
not recommended [79], since reported AST of rifampin, rifabutin, ethambutol and 
streptomycin do not predict therapeutic efficacy. However, we recommend primary testing of 
amikacin against MAC isolates, extrapolating breakpoints from rapidly growing mycobacteria 
(susceptible: ≤16 mg/L; intermediate: 32 mg/L; resistant: ≥64 mg/L) [91,96], since amikacin 
is a key component of regimens to treat complicated MAC infections and since it has often 
been used in the pre- and postoperative phase of M. chimaera infection [7,15,82].  
8. Surgical intervention 
8.1. Pre- and perioperative management  
Recommendations on the perioperative management and the hospital epidemiology 
precautions for patients who require repeat surgery in the treatment of cardiovascular 
infection due to M. chimaera are summarized in Table VIII. Coronary angiography and 
intraoperative echocardiography should be performed as recommended by the ESC guidelines 
[31]. Recommendations for SSI prophylaxis for cardiac procedures should be followed [97]. 
In addition, M. chimaera treatment should be continued in the perioperative phase. Isolation 
precautions in the pre- and post-anaesthesia care unit are not required. 
8.2. Surgical approach 
Recommendation 
• Revision surgery with removal of all cardiovascular prosthetic material should be 
considered (Class IIa, Level C). Source control should include all extracardiac foci in 
addition to cardiovascular sites (Class IIa, Level C). 
Cardiovascular M. chimaera infection is associated with a high morbidity and 
mortality due, in part, to both dissemination of infection and high affinity of mycobacteria to 
attach to, and form biofilm on, the surface of cardiovascular prosthetic devices. Many patients 
managed conservatively with antimycobacterial treatment alone have either failed to improve 
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or have experienced breakthrough infection [3,7]. Hence, redo surgery with removal of all 
cardiovascular prosthetic material should be considered. Intraoperative mycobacterial tissue 
cultures and mycobacterium genus-specific PCR followed by sequencing must be obtained 
because culture results have been positive in the bulk of patients, regardless of whether or not 
anti-mycobacterial therapy has been previously administered [9]. Removal of all intracardiac 
foreign material is strongly recommended due to mycobacterial biofilm formation, even if a 
cardiac valve/vascular graft is functioning well. Additionally, extraction and replacement of 
any other cardiovascular prosthetic devices is recommended. Patients with localized (e.g. 
sternal surgical site) infections should undergo extensive debridement with removal of sternal 
metal wires [3,7,9,49]. Nevertheless, there are patients in whom extensive surgical 
intervention is not feasible, usually due to a patient’s underlying co-morbid conditions, and an 
individualized approach to infection management is needed. The optimal timing of a redo 
cardiovascular surgical procedure remains undefined. If feasible, it may be prudent to wait for 
clearance of mycobacterial blood cultures. Several centres advise preoperative anti-
mycobacterial therapy for 6–12 weeks to reduce the chance of planktonic forms seeding 
replacement devices [7,49]. Whether antimycobacterial therapy prior to surgery and removal 
of all prosthetic material influences infection cure rates remains to be defined by longer 
follow-up periods with a larger number of patients [7,9,13,48]. 
There is no preference for a specific valve/graft substitute as there are insufficient data 
to make a recommendation. The use of cryopreserved homografts should be considered in the 
setting of aortic graft infections and annular abscess formation. However, availability of 
human tissue for transplantation is an important consideration as not all institutions have 
access, especially in urgent cases. Heart transplantation is considered in extreme infective 
endocarditis cases where operative procedures fail, provided repeated blood cultures are 
negative. Due to the need for immunosuppression, heart transplantation for disseminated M. 
chimaera infection generally has not been considered a feasible option. Extrathoracic and 
disseminated M. chimaera infections are common. Ideally, non-cardiovascular foci (e.g. bone 
infections and abscesses) should be eradicated before cardiovascular surgical intervention 
[22]. If cardiac surgery cannot be delayed, distant infection sites should be eradicated before 
the end of antimycobacterial therapy. In some cases, surgical intervention at non-
cardiovascular infection sites will also be required. 
9. Follow-up and prognosis 
Relapse is a major complication of disseminated M. chimaera infection that often 
requires repetitive surgery involving cardiovascular and/or non-cardiovascular sites [7,9,13]. 
Factors associated with relapse are included in Table IX. Currently, the actual infection 
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relapse risk is undefined, in part related to the extended follow-up that is required after 
completion of antimycobacterial therapy to determine whether cure of infection has been 
achieved. Among the few reported survivors with defined follow-up, the relapse rate has been 
as high as 30–50% [7,9]. However, the retrospective nature of most case series with broad-
ranging follow-up periods and the prolonged incubation period of infection due to M. 
chimaera make quantitating outcome analyses difficult. Elevated mortality is another 
troubling outcome, with recent case series reporting mortality rates of 20–67% 
[7,9,13,14,21,30].  
10. Considerations for patient notification, screening, and investigation 
Recommendations 
• Consider patient and provider notification regarding risk and signs/symptoms of 
infection (Class IIa, Level C). 
• Additional case-finding through investigation and testing of patients with a history of 
exposure to 3T-HCD should be restricted to those who are symptomatic (Table X) 
(Class IIa, Level C). 
Patients who have undergone CPB should be educated about the risks, until they reach 
the fifth-year anniversary of their surgery, so that patients can seek medical care if warning 
signs and symptoms of M. chimaera infection develop. Given the higher yield among 
hospitals that have already had a case (in addition to the medico-legal component), this 
recommendation applies in particular to sites with at least one case. 
Providers who see exposed patients, such as primary care providers, should be notified 
to increase awareness of the risks associated with exposure to CPB. Provider awareness can 
be achieved through public health alerts, webinars, or by e-mails to various healthcare-
provider professional societies. Additionally, the use of ‘alerts’ embedded in electronic 
medical records of patients who underwent open-chest surgery and who may be at risk of 
future M. chimaera infection may allow providers to more rapidly diagnose and refer patients 
for infectious disease consultation. 
Investigators in the USA have implemented both patient and healthcare provider 
notifications to help identify potentially infected patients early [98,99]. In 2016, CDC issued a 
recommendation that all US healthcare facilities using the 3T-HCD notify patients who 
underwent open-chest cardiac surgery using these devices of the risk of M. chimaera 
infection. Patient notification letters provided information on the signs and symptoms of a 
possible infection and patients were encouraged to promptly seek medical care if experiencing 
any of these symptoms [99]. To date, a number of infected patients and clusters have been 
identified through this strategy, including one institution with a large outbreak that was not 
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previously recognized [18,98]. Additionally, consideration should be given to patients who 
will be undergoing cardiac surgery with a 3T-HCD to notify them of the potential risks of M. 
chimaera infection through a preoperative informed consent process [100]. 
The task force recommends that additional case-finding through evaluation and testing 
be restricted to patients previously exposed to HCD who develop symptoms (Table X), given 
the low disease incidence, the significant psychological impact and the overall costs of 
screening. Additional cases of M. chimaera infections might be found by review of: (i) non-
respiratory M. avium complex isolates with former CPB with the use of 3T-HCD within five 
to six years; (ii) histopathology reports of culture-negative cardiovascular infections with 
former CPB with the use of 3T-HCD within five to six years; (iii) sarcoidosis cases and 
former CPB with the use of 3T-HCD within five to six years.  
Recommendations regarding systematic screening for M. chimaera infection among 
asymptomatic patients with a prior history of open-chest surgery have been considered by 
several health agencies, with the assumption that this might result in an earlier diagnosis and a 
reduction in dissemination of infection. However, the time between index surgery and 
diagnosis of infection has been broad and ranged between six weeks to more than five years 
(median: 15 months) [9,12]; thus screening, if performed, would have to be done on a 
recurrent basis. Moreover, screening tools, such as routine and/or mycobacterial blood 
cultures, have a low sensitivity for detecting M. chimaera [7]. In addition, it is not clear which 
screening tests might provide the greatest yield.  
11. Prevention, infection control measures and reporting obligation 
Co-ordination and surveillance of risk mitigation measures (Table XI) should be the 
responsibility of each institution’s infection prevention and control experts, who are familiar 
with the biology of M. chimaera and its proclivity to cause device contamination in certain 
settings. Institutions should also refer to relevant guidance from regional regulatory and 
public health providers. In particular, the preferential adherence of mycobacteria to surfaces at 
air–water interfaces and the high cell-surface hydrophobicity contribute to the disinfection 
tolerance of mycobacteria [34,41,103–106]. Additionally, NTM can grow over a very wide 
temperature range (15–45°C) and survive at 55–60°C [65]. Since decontamination measures 
often fail [41,91,92] and since intensified cleaning and disinfection might lead to device 
damage [36,106], facilities can either use other HCDs or they are strongly advised to separate 
HCDs from the OR room air volume by: (i) placing HCDs in dedicated utility rooms adjacent 
to the OR [33,102,107,108]; or (ii) encasing them with controlled air extraction via a duct to 
the theatre exhaust conduit [41]. However, encasings that are engineered and built by 
hospitals may alter the function of the HCD, and the potential for such changes in function 
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should be taken into consideration when implementing such interventions. Removal of HCDs 
from the OR may require reconfiguration of ORs and the theatre design may prevent removal 
of the implicated HCDs [108]. If HCD exhaust air cannot be reliably separated from the OR, 
HCDs should be placed as far as possible away from the operating field and the vent exhaust 
should be directed away from the patient and the surgical instruments [107,108,109]. These 
measures should be considered only temporary, as the risk of airborne transmission is not 
eliminated. Additionally, cross-contamination by exchanging tubing from one HCD to 
another should be avoided [33,110].  
Institutions should continue to follow updated manufacturer instructions for cleaning 
and disinfection of these devices [110]. More recently, LivaNova issued updated instructions 
in the monitoring of hydrogen peroxide concentrations in the HCD water circuit [110]. The 
manufacturer also implemented device modifications consisting of a vacuum and sealing 
upgrade and an aerosol collection kit in 2017 [42]. Currently, we cannot make a statement 
with regard to the safety of these modifications due to a lack of data. Additionally, LivaNova 
offers a refurbishing and disinfection programme of their 3T-HCD with replacement of 
accessories, tubing and connectors to prevent recontamination [34]. However, there is no 
consistent evidence that M. chimaera can be eradicated from any HCD model once 
contaminated. 
Some advocate routine microbiological screening of HCDs. However, there is no 
standardization with regard to the collection of samples and the laboratory methods used, with 
differences among environmental laboratories. In addition, the degree of device 
contamination required to generate positive HCD water and air cultures is unknown, thus the 
ultimate benefit is uncertain. Water samples of 1000 mL cultured in Mycobacteria Growth 
Indicator Tubes (MGITTM) medium had the highest sensitivity for M. chimaera detection in a 
recent study [112]. Routine surveillance is not widely adopted due to slow growth of this 
organism in laboratory cultures, which can take up to eight weeks; this delay may lead to the 
use of contaminated machines during this prolonged incubation period [108,112].  
Additionally, sampling and testing protocols have not been validated, with some concern for 
false-negative results.  
Reporting of adverse events that occur as a result of medical device use is encouraged 
in most jurisdictions. Healthcare professionals should report cases of M. chimaera infection 
thought to be associated with use of a contaminated HCD to the respective regulatory 
authority [101].  
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12. Areas of future research 
As highlighted throughout this document, there are many aspects of diagnosis, 
management, and prevention that need further research. The results of subsequent 
investigations will not only be critical with regard to improved understanding of post-
cardiovascular surgical M. chimaera infections, but will also help to gain insight into other 
types of mycobacterial infections acquired in the operative setting [113]. 
The extent of this outbreak and especially the risk to the paediatric population are 
undefined [7,114]. Case-finding strategies, device safety alerts, and microbiological 
diagnostics need improvements [107]. Due to the rarity of the disease, the task force strongly 
encourages multi-centre outcomes data collections to address key questions regarding optimal 
medical therapy, which is currently undefined. There are currently efforts to create a US 
registry of patients infected with NTM after exposure to HCDs during cardiac surgery, and 
the registry hopes to provide more details and guidance on the epidemiology, clinical 
manifestations, treatment, and outcomes for patients with related infections. Additional details 
regarding enrolling patients to the registry can be found at http://www.NTMInfect.org. The 
correlation between treatment response and in-vitro susceptibility of the isolates to anti-
mycobacterial drugs needs further study. The role of therapeutic drug monitoring also 
requires clarification [7]. Collaborative discussions between medical device manufacturers, 
engineers, and hospital epidemiology experts will be needed as new HCDs are designed. 
Additionally, reliable decontamination and identification of agents that can disrupt biofilms 
and increase chlorine susceptibility of mycobacteria are required [115]. Moreover, other 
mycobacteria [46,101,116] as well as fungi, Legionella spp., non-fermenters such as 
Pseudomonas aeruginosa, coagulase-negative staphylococci, Micrococcus spp. and Gram-
positive rods may also colonize HCDs [104] although the clinical relevance of colonization of 
HCDs with one or more of these organisms is unclear [46,116].  
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Table Ia 
Evidence-based scoring system (adapted from [31])  
Classes of recommendation Definition Suggested wording to use 
Class I Evidence and/or general 
agreement that a given 
treatment or procedure is 
beneficial, useful, effective 
Is recommended/is indicated 
Class II Conflicting evidence and/or a 
divergence of opinion about 
the usefulness/efficacy of the 
given treatment or procedure 
 
Class IIa Weight of evidence/opinion 
is in favour of 
usefulness/efficacy 
Should be considered 
Class IIb Usefulness/efficacy is less 
well established by 
evidence/opinion 
May be considered 
Class III Evidence or general 
agreement that the given 
treatment or procedure is not 
useful/effective and in some 
cases may be harmful 
Is not recommended 
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Table Ib 
Levels of evidence (adapted from [31]) 
Level of evidence A Data derived from multiple, randomized 
clinical trials or meta-analyses 
Level of evidence B Data derived from a single randomized 
clinical trial or large non-randomized studies 
Level of evidence C Consensus of opinion of the experts and/or 
small studies, retrospective studies, registries 
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Table II 
Cardiovascular surgical procedures at risk of Mycobacterium chimaera infections  
Procedure Class Level  
Cardiopulmonary bypass surgery involving a 3T-HCD and one or more of the 
following: 
– Prosthetic material used for cardiac valve or aortic repair [7,21]a 
– Mechanical circulatory support device implantation [19] 
– Implant of palliative shunts, conduits or other prostheses for congenital 
heart disease (CHD) [7,20,49]3 
– Coronary artery bypass grafting [9,30]b  
– Heart transplantation [13] 
IIa C 
aAortic surgery is reported to have the highest risk [14]. 
bCoronary artery bypass grafting bears the lowest risk [9,30]. 
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Table III 
Classification of choroidal lesions based on multi-modal imaging (adapted from [52]) 
Imaging modality Active lesion Inactive lesion in regression 
Fundus photography 
Shape 
Border 
Size 
Colour 
 
Ovoid to round 
Indistinct  
Small (<1 disc diameter) 
Yellow–white  
 
Ovoid to round 
Well-defined 
Small (<1 disc diameter) 
Whitisha 
Fluorescein angiography 
Early 
Late 
 
Hypofluorescent 
Hyperfluorescent 
 
Hyperfluorescent 
Hyperfluorescent 
Indocyanine green 
angiography 
Hypofluorescent Hypofluorescent 
Fundus autofluorescence Hyperautofluorescent Hypoautofluorescent 
EDI-OCT 
Shape 
  
Internal reflectivity 
Transmission effect 
 
Full-thickness, round, well-
defined borders 
Hyporeflective 
Increased 
 
Poorly defined margins 
 
Similar to the choroid 
Increased 
EDI-OCT, spectral-domain optical coherence tomography including enhanced depth imaging. 
aPigmentation might develop and would be a sign of inactivity, but has not been observed so 
far. 
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Table IV 
Proposed screening and follow-up examinations for patients with suspected or confirmed 
Mycobacterium chimaera ocular infection (adapted from [52]) 
Timepoint Imaging modalities Class Level 
Baseline ocular examination Complete ophthalmic examination  
Visual acuity 
Intraocular pressure measurement 
Anterior and posterior segment slit-lamp 
examination including dilated fundus 
biomicroscopy  
Multi-modal imaging testing 
Wide-angle fundus photography 
FA/ICGA (if possible, by using a wide-angle 
camera) 
FAF 
EDI-OCT 
OCTA (if available) 
IIa
  
C 
Follow-up ocular 
examinations 
   
Absence of active ocular 
disease  
or  
Discontinuation of 
mycobacterial therapy 
Clinical follow-up visits every 2 months with 
dilated fundusa  
 
Multi-modal imaging tests every 4 monthsa 
IIb C 
Presence of active ocular 
diseaseb 
Clinical follow-up visits every month with 
dilated fundus examination  
Multi-modal imaging tests every 2 months 
IIb C 
EDI-OCT, spectral-domain optical coherence tomography including enhanced depth imaging; 
FAF, fundus autofluorescence imaging; FA/ICGA, fluorescein angiography/indocyanine 
green (ICG) angiography; OCTA, optical coherence tomography angiography. 
aAfter one year of quiescence, the follow-up intervals might be extended to 3 and 6 months, 
respectively. 
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Table V 
Diagnostic criteria of disseminated Mycobacterium chimaera infection (adapted from [7]) 
Exposure assessment History of surgery requiring cardiopulmonary bypass 
surgery prior to symptoms of infection 
Laboratory assessment  
 Culturea,b M. chimaera*-positive cultures obtained from a sterile site 
(blood, purulent material, tissue biopsy, or implanted 
prosthetic material).  
Mycobacterial blood cultures (BacTec myco Lytic/F bottles 
BD Bioscience); VersaTrek (Thermo Fisher) use of Isolator 
tubes (Isolator 10, Oxoid; Isostatw System, WampoleTM) 
can either be directly inoculated at the point-of-care if the 
laboratory is on site or alternatively citrate/heparin blood 
should be sent to a mycobacteriology laboratory in case 
blood culture bottles are not available. 
 PCRc Mycobacterium genus-specific PCR obtained from an 
invasive sample (blood, purulent material, tissue biopsy, or 
implanted prosthetic material). 
Clinical assessmentd  
Cardiovascular 
manifestations 
Prosthetic valve endocarditis 
 Prosthetic vascular graft infection 
 Myocarditis  
 Pseudoaneurysm formation 
Localized infections Sternotomy wound infection 
 Mediastinitis 
Extrathoracic 
manifestationse 
Bloodstream infection and disseminated infection including 
embolic and immunologic manifestations 
 Splenomegaly 
 Bone marrow involvement with cytopenia 
 Bone infection (arthritis, osteomyelitis) 
 Pneumonitis 
 Hepatitis 
 Nephritis 
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Skin infection 
 Chorioretinitis 
 Cerebral vasculitis 
Constitutional symptoms Fever 
Fatigue 
Weight loss 
Night sweats 
Joint pain 
Shortness of breath 
 Infants: failure to thrive/febrile episodes 
Histopathologyf Detection of non-caseating granuloma and foamy/swollen 
macrophages with/without acid fast bacilli in cardiac tissue 
in the proximity of the prosthetic material 
PCR, polymerase chain reaction. 
aCollect three heparin blood cultures. 
bTissue and bone acid-fast staining and mycobacterial cultures and acid-fast staining 
recommended. Submission to laboratory in native, aseptic container. Positive cultures 
identified as M. avium complex micro-organisms should undergo 16S rDNA (or alternatives 
such as hsp65/ITS) gene sequencing for species identification.  
cPerform a mycobacterium genus-specific PCR or, if available, an M. chimaera-specific PCR. 
The species-specific PCR is likely more sensitive than a mycobacterium genus-specific PCR. 
dBased on current evidence, asymptomatic individuals with previous open cardiac surgery 
should not undergo testing for M. chimaera. 
eM. chimaera positive isolates should be whole genome sequenced in order to confirm 
relatedness to the global outbreak strain [28]. If a laboratory confirms the organism’s identity 
is consistent with the outbreak strain, it is recommended that healthcare authorities be 
informed. 
fOnce a post-cardiopulmonary bypass M. chimaera infection is diagnosed at a hospital, 
providers should review every diagnosis of sarcoidosis, fever of unknown origin, and 
unknown vasculitis to exclude M. chimaera infection [15]. 
Confirmed cases: meet clinical and exposure criteria AND M. chimaera is detected by culture 
and PCR identification from invasive sample (blood, purulent material, biopsy or prosthetic 
material). 
Probable cases: meet clinical and exposure criteria AND M. chimaera is detected by PCR not 
by culture from invasive sample (blood, purulent material, biopsy or prosthetic material) 
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operating theatre OR M. avium complex is detected by culture and PCR identification from 
invasive sample (blood, purulent material, biopsy or prosthetic material) OR detection of non-
caseating granuloma and foamy/swollen macrophages with acid-fast bacilli in cardiac tissue 
in the proximity of the prosthetic material or in specimen from sternotomy wound. 
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Table VI 
Potential regimens for the antimicrobial treatment of Mycobacterium chimaera infection 
Type of Mycobacterium chimaera strain Suggested regimen Class Level 
Wild-type Mycobacterium chimaera 
   
First-line therapy Azithromycin, rifampin (rifabutin), ethambutol, amikacina  I C 
Second-line therapy Clarithromycin, rifabutin (rifampin), ethambutol, amikacina I C 
Drug-resistant M. chimaerab 
   
Clarithromycin Rifabutin/rifampin, ethambutol, amikacin, clofazimineb,c,d I C 
Amikacin Clarithromycin, rifabutin/rifampin, ethambutol, clofaziminec,d   
bConsider repeat testing since resistances are rare. Providers should seek expert consultation in all these cases. 
aAmikacin is recommended and should be continued as long as it is tolerated via peripherally inserted central catheter (PICC) as outpatient 
parenteral antibiotic therapy (OPAT) (Class IIa, Level C). 
cAdding clofazimine as an additional antimicrobial agent may be considered (Class IIb, Level C). There is an in-vitro synergy for clofazimine 
and amikacin [80].  
dAny other medication (moxifloxacin, linezolid, bedaquiline) should be administered after expert consultation and if resistance test results from 
reference laboratories are available.  
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Table VII 
Drugs used in the management of adult patients with Mycobacterium chimaera infection, recommended dosages, route and common adverse 
drug reactions 
Antibiotic Dosagea Route Comments/side-effects 
Azithromycin 250–500 mg qdb 
or  
500 mg 3× per week 
Oral/IV May prolong QTc interval. Reversible hearing impairment. Diarrhoea. Toxicities are 
dose- and serum-level-related. 
Clarithromycin 500 mg bidb Oral/IV May prolong QTc-interval. Frequent gastrointestinal toxicities like metallic taste, 
diarrhoea, nausea, vomiting and elevated liver function tests. Toxicities are dose- and 
serum-level-related.  
Ethambutol 15 mg/kg body weight qd 
25 mg/kg 3× per weekc  
Oral  Retrobulbar optic neuritis with visual loss; baseline and as needed testing of visual 
acuity and colour discrimination (Ishihara tests) is recommended as well as careful 
instructions to patientd 
Rifampin 
 
600 mg qd  Oral/IV 
 
Monitor for hepatotoxicity; drugs metabolized by cytochrome P-450 may require 
dose adjustments (e.g. macrolides, oral contraceptives, methadone, warfarin, and 
ART). Gastrointestinal reactions are common; orange discoloration of bodily fluids. 
Hypersensitivity reaction.  
Rifabutin 150–300 mg qd  
or 
150–300 mg 3× per 
weeke 
Oral/IV 
 
Monitor for hepatotoxicity; drugs metabolized by cytochrome P-450 may require 
dose adjustments (e.g. macrolides, oral contraceptives, methadone, warfarin, and 
ART). Fever. Anterior uveitis; bone marrow suppression; pseudojaundice (skin 
discoloration with normal bilirubin); polyarthralgias; ‘flu-like’ illness.  
Amikacin 15 mg/kg qdf  
or 
IV Monitoring of renal function and vestibular/hearing function necessary. TDM 
required.  
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25 mg/kg 3× per week 
Companion drugs 
(not clearly proven 
efficacy) 
   
Clofazimine 100–200 mg qd Oral May prolong QTc interval. Consider reduction of dosage to 5× per week in case of 
severe skin discoloration. Skin discoloration is usually reversible. Abdominal pain 
and/or eye symptoms.  
Bedaquiline Weeks 1+2: 400 mg qd  
Weeks 3–24: 200 mg 3× 
per week 
Oral Take with food. Electrolyte abnormalities, hepatotoxicity, pancreatitis, myopathy. 
May prolong QTc interval, especially when concurrently used with moxifloxacin. 
Very little efficacy data [84]. 
Moxifloxacin 400 mg qd Oral/IV Gastrointestinal disturbance: nausea and bloating. Neurologic effects: dizziness, 
insomnia, tremulousness, and headache. May prolong QTc interval. Very little 
efficacy data [81]. 
Linezolidb 600 mg qd/bid Oral/IV Risk of lactic acidosis, bone marrow suppression, and neurological toxicity 
(peripheral neuropathy). 
qd, once daily; bid, twice a day; tid, three times a day; qid, four times a day; IV, intravenous; ART, antiretroviral therapy; TDM, therapeutic drug 
monitoring. 
aDosage may need adjustment with age, body weight. 
bBe aware of drug–drug interactions with rifamycins. In case of combination therapy of azithromycin with rifampicin the 250 mg qd dosage of 
azithromycin might be too low [88,89].  
cEthambutol dose for older patients may be reduced to daily 25 mg/kg due to toxicity.  
dRefer to ophthalmologists if optic neuritis suspected. 
eA dose reduction of rifabutin 150–300 mg 3× per week may be considered if daily treatment is not well tolerated. 
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fIn case of long-term treatment, a reduction of dosage to 7 mg/kg per dose may be considered. Alternative dosage three times weekly, especially 
for patients aged >60 years.  
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Table VIII 
Recommendations on the perioperative management of Mycobacterium chimaera-infected 
patients 
Recommendation Class Level 
Perform coronary angiography and intraoperative echocardiography I C 
– Antimicrobial treatment 
– The usual surgical perioperative prophylaxis for cardiac procedures is 
recommended [97] 
IIa C 
– Continue M. chimaera treatment perioperatively I C 
Pre- and post-anaesthesia care unit 
– No isolation precautions in the pre- and post-anaesthesia care unit 
– Schedule subsequent operations at least 30 min later to facilitate an 
OR ‘wash-out phase’ may be considered 
– Change the filters and the anaesthetic tubing and the use of a 
mycobactericidal oxidizing disinfectant may be considered [115] 
– To potentially avoid theoretical airway colonization in subsequent 
patients, consider processing the warming device  
– Frequent staff turnover for breaks of nurses, scrub technicians and 
anaesthesia is not recommended 
– Change of clothes or wearing of paper gowns over scrub clothing to be 
discarded later is not recommended 
 
I 
IIb 
 
IIb 
 
IIb 
 
III 
 
III 
 
 
C 
C 
 
C 
 
C 
 
C 
 
C 
 
OR, operating room. 
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Table IX 
Factors likely associated with Mycobacterium chimaera relapsesa 
Delayed antimycobacterial treatment 
No ‘lead-in’ preoperative antimycobacterial treatment 
Positive M. chimaera valve culture 
Cardiac or extrathoracic prosthetic material 
Disseminated disease with distant foci and abscess formation 
Macrolide and/or amikacin resistant M. chimaera strain 
aThese factors are based on expert consensus. 
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Table X 
Recommendations for Mycobacterium chimaera infection patient/provider notification, 
additional case-finding and investigation, and screening 
Recommendation Class Level 
• Patient notification should be considered. However, to date, such 
notifications have not contributed substantially to case-finding. 
Discussion and input by health department authorities and likely 
consumer stakeholders needed. 
IIa C 
• Provider notification should be considered and has been successful in 
case detection. M. chimaera infection can occur among patients with 
open-heart surgery with CPB after 2008 (earliest sentinel surgery) and 
before the introduction of effective risk mitigation measures. 
IIa C 
• Additional case-finding through evaluation and testing of patients with a 
history of exposure to (3T-)HCD (past 5–6 years) should be restricted to 
those who are symptomatic and/or have at least one of the following: 
– Culture-negative prosthetic valve endocarditis 
– Culture-negative aortic graft infection 
– Mechanical circulatory support device infection 
– Culture-negative sternal osteomyelitis and/or mediastinitis 
– Fever of unknown origin 
– Vasculitis 
– Undetermined systemic disease, sarcoidosis-like or other 
granulomatous disease 
IIa C 
• Diagnostic measures:  
– Physical examination including ophthalmoscopy, medical history 
(weight loss, night sweats, fever, skeletal pain, etc.), blood tests (ESR, 
CRP, complete blood count, transaminases, creatinine) 
– Mycobacterial blood cultures (BacTec myco Lytic/F bottles BD 
Bioscience); VersaTrek (Thermo Fisher) use of Isolator tubes (Isolator 
10, Oxoid; Isostatw System, WampoleTM).  
– Tissue mycobacterial cultures, broad range and mycobacterium-genus 
specific PCR and histopathological work-up in case of reoperative 
heart surgery or surgery of distant foci. 
I C 
• Additional case-finding tools: IIb C 
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– Review non-respiratory M. avium complex isolates and identify 
patients with former CPB with the use of 3T-HCD within 5–6 years.  
– Review culture-negative prosthetic valve endocarditis/aortic graft 
infections and histopathology reports for manifestations compatible 
with a probable post-cardiac-surgery M. chimaera disease. 
– Review sarcoidosis cases with former CPB with former CPB within 5–
6 years.  
– Review histopathology reports from excised heart valves/aortic grafts 
for granulomatous tissue formation. 
• Routine screening of asymptomatic patients with a history of exposure to 
(3T-)HCD is not recommended. 
III C 
HCD, heater–cooler device; CPB, cardiopulmonary bypass; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; PCR, polymerase chain reaction. 
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Table XI 
Prevention of future Mycobacterium chimaera exposure  
Topic Recommendations Class Level 
General guidelines for HCDs    
HCD traceability Register HCD, patient, and date of use [33] I C 
Water safety Use only sterile or all-bacteria-filtered-water (0.22 mm or 
less) including when making ice needed for patient 
cooling [101] 
IIa C 
Use cleaning and disinfection 
procedures according to the 
manufacturer 
Maintain log of cleaning and disinfection.  
Caveat: Current decontamination protocols may be 
insufficient due to biofilm formation by mycobacteria in 
the implicated devices [41,102]. Biofilm formation can be 
seen by discoloration/cloudiness in the fluid lines or 
circuits [101]. 
I C 
Separate HCD (other than 3T) exhaust 
air from ORa 
Separation of HCDs from air volume of critical medical 
areas such as operating rooms may be considered. 
IIb C 
Remove/replace contaminated 3T-HCD 
from service 
All 3T-HCDs manufactured should ideally be removed 
from service or alternatively measures ensuring strict 
separation between air in the OR and the potentially 
contaminated air around HCD should be taken. 
I C 
Separate 3T-HCD exhaust air from OR Guarantee strict separation of HCDs from air volume of I C 
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critical medical areas such as operating rooms [35,102]. 
Place HCD outside the OR, whenever possible. Encase 
HCD connected to the OR exhaust. 
Testing of HCD    
Non-tuberculous mycobacterium 
surveillance 
Use the ‘Protocol for case detection, laboratory diagnosis 
and environmental testing of M. chimaera infections 
potentially associated with heater–cooler units’ by ECDC 
[64]. 
IIa C 
OR, operating room; HCD, heater–cooler device; CPB, cardiopulmonary bypass; ECDC, European Centre for Disease Prevention and Control. 
aAlthough contamination of other device types with M. chimaera has been described, no case of infection has been linked to other device types 
neither is there evidence of aerosolization with other device types in limited investigations so far [28].
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Figure 1. Algorithm for microbiological diagnosis of suspected cardiovascular infections including 
possible Mycobacterium chimaera infections (adapted from [31]). *Among patients meeting 
exposure criterion and a having a suggestive clinic, consider upfront AFB cultures. AFB, acid-fast 
bacilli; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; PCR, polymerase 
chain reaction; ITS, internal transcribed spacer region. 
 
 
